公司在控股巨石生物后，战略转型至生物创新药领域，打造领先的创新生物医药平台成为了公司的长期 发展战略。巨石生物在生物创新药领域已经构建了具有竞争力的研发体系和具有市场前景的产品管线布 局，多款产品的研发及商业化取得重要进展，覆盖多元化的临床需求及潜在重磅产品的潜力。巨石生物 日益成为公司重要的增长引擎。公司坚定看好巨石生物的发展前景，收购其少数股权有利于进一步完善 公司业务布局、落实发展战略、促进可持续发展，符合公司长远战略发展规划。 智通财经APP讯，新诺威(300765.SZ)发布公告，公司拟以现金购买石药集团恩必普药业有限公司(以下 简称"恩必普药业")持有的石药集团巨石生物制药有限公司(以下简称"巨石生物"或"标的公司")29%股权 (以下简称"本次交易")。本次交易完成后，公司持有巨石生物的股权比例将由51%增加至80%。本次交 易标的股权的转让价款为11亿元。 ...

Core Viewpoint - The company intends to acquire a 29% stake in Giant Stone Biopharmaceutical Co., Ltd. from Enbip Pharmaceutical Co., Ltd. for 1.1 billion yuan, increasing its ownership from 51% to 80% [1] Group 1: Transaction Details - The transaction involves a cash purchase of 1.1 billion yuan for the stake in Giant Stone Biopharmaceutical [1] - Upon completion, the company's stake in Giant Stone will rise to 80% [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategic shift towards the biopharmaceutical innovation sector, aiming to establish a leading innovative biopharmaceutical platform [1] - Giant Stone has developed a competitive R&D system and a promising product pipeline in the biopharmaceutical innovation field, with significant progress in the development and commercialization of multiple products [1] - The company views Giant Stone as a crucial growth engine and believes that acquiring the minority stake will enhance its business layout, implement its development strategy, and promote sustainable growth [1]

Group 1 - The company Xinnoway (300765.SZ) signed a share transfer agreement with Enbipu Pharmaceutical to acquire a 29% stake in Jushi Biotech for a cash consideration of 1.1 billion yuan, increasing its ownership from 51% to 80% [1] - The transaction is based on an asset evaluation report from a qualified institution in accordance with the Securities Law [1] Group 2 - Jushi Biotech is an innovative biopharmaceutical company focused on antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with a strong emphasis on independent research and development [2] - The company has established a competitive R&D system and a promising product pipeline, covering three major therapeutic areas: oncology, autoimmune diseases, and major infectious diseases [2] - Jushi Biotech has numerous projects in development, with key products like Enlansumab and Omabuzumab set to launch in 2024, and several others in critical clinical trial phases [2] - The company has become a benchmark in the domestic monoclonal antibody and ADC innovation drug industry, providing safe, effective, and accessible biotherapy solutions globally [2] - Jushi Biotech is one of the first domestic companies to achieve mRNA vaccine industrialization and has a comprehensive layout in ADC and monoclonal antibody pipelines [2]

Core Viewpoint - The company, Sinovac Biotech Ltd. (科兴制药), aims to enhance its strategic layout of "innovation + internationalization" by accelerating overseas business development and improving its overall competitiveness and international brand image through the issuance of H-shares and listing on the Hong Kong Stock Exchange [1] Group 1 - The company plans to issue H-shares to optimize its capital structure [1] - The move is intended to leverage the advantages of international capital markets for diversified financing channels [1] - The initiative is part of the company's strategy to deepen its presence in the global market [1]

2025年9月29日发布的细则显示，科兴生物制药股份有限公司为适应战略发展需要，根据相关法规及章 程设立董事会战略委员会并制定工作细则。战略委员会由4名董事组成，其中至少1名独立董事，任期与 董事会一致。其主要职责是对公司发展战略、重大投资等事项研究并提建议，对实施情况检查。决策按 特定程序进行，议事有明确规则，会议记录等资料保存不少于10年。细则经董事会审议通过后，自H股 在港交所挂牌上市日起生效，原细则自动失效。 ...

Core Viewpoint - The company announced the approval of a clinical trial application for HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - HLX43 is a targeted PD-L1 antibody-drug conjugate (ADC) developed by the company, utilizing a novel DNA topoisomerase I inhibitor small molecule toxin linked to a self-developed PD-L1 targeting antibody [1] - HLX07 is an innovative biological drug developed by the company targeting the EGFR pathway, intended for the treatment of advanced solid tumors [1] Group 2: Clinical Trials - The 1b/2 phase clinical trial results for HLX07 in combination with chemotherapy for advanced solid tumors showed good safety and tolerability [1] - Multiple phase 2 clinical studies for HLX07 are currently underway in China, including studies for HLX07 as a monotherapy for advanced cutaneous squamous cell carcinoma (CSCC) and in combination with Hanshu® for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) [1]

Core Viewpoint - The announcement highlights the approval of a clinical trial application for HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - HLX43 is a novel antibody-drug conjugate (ADC) targeting PD-L1, developed by the company using a licensed small molecule toxin-peptide linker and its own PD-L1 targeting antibody [1] - HLX07 is an innovative biological drug developed by the company targeting EGFR, intended for the treatment of advanced solid tumors [1] Group 2: Clinical Trials - The 1b/2 phase clinical study of HLX07 in combination with chemotherapy for advanced solid tumors showed good safety and tolerability as of February 2023 [1] - Multiple phase 2 clinical studies of HLX07 are currently underway in China, including trials for advanced cutaneous squamous cell carcinoma (CSCC) and advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) [1]

Core Viewpoint - Tian Tan Biological Products Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of "human fibrinogen" [1] Group 1 - Tian Tan Kunming, a subsidiary of Tian Tan Biological, is authorized to conduct clinical trials for "human fibrinogen" [1]

天坛昆明"人纤维蛋白原"产品后续尚需完成开展临床试验、提交药品上市许可申请、通过国家药品监督 管理局药品审评中心审评及国家药品监督管理局审批、获得药品注册证书等审批程序，方可实现生产及 上市销售。 天坛生物（600161）(600161.SH)发布公告，近日，公司下属国药集团昆明血液制品有限公司(简称"天坛 昆明")获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意天坛昆明开展"人纤维蛋白 原"临床试验。 ...

Core Viewpoint - Tian Tan Biological (600161.SH) has received approval from the National Medical Products Administration for clinical trials of its "human fibrinogen" product, marking a significant step towards potential market entry [1] Group 1: Company Developments - Tian Tan's subsidiary, Kunming Blood Products Co., Ltd., has been granted the Clinical Trial Approval Notice for "human fibrinogen" [1] - The company must complete several steps, including conducting clinical trials, submitting a drug marketing application, and obtaining necessary approvals before production and sales can commence [1] Group 2: Regulatory Environment - The approval from the National Medical Products Administration is a crucial regulatory milestone for the company [1] - The process includes clinical trials, review by the drug evaluation center, and final approval from the National Medical Products Administration [1]